[PDF][PDF] Canada: Health system review
GP Marchildon, World Health Organization - 2013 - apps.who.int
Canada is a high-income country with a population of 33 million. Life expectancy is high
compared with most OECD countries; however, infant and maternal mortality rates tend to be …
compared with most OECD countries; however, infant and maternal mortality rates tend to be …
Policy options for pharmaceutical pricing and purchasing: issues for low-and middle-income countries
TA Nguyen, R Knight, EE Roughead… - Health Policy and …, 2015 - academic.oup.com
Pharmaceutical expenditure is rising globally. Most high-income countries have exercised
pricing or purchasing strategies to address this pressure. Low-and middle-income countries …
pricing or purchasing strategies to address this pressure. Low-and middle-income countries …
[图书][B] Health Systems in Transition Third Edition
The health care system in Canada receives a great deal of international attention, but it is
subject to considerable critique and debate locally. Health Systems in Transition: Canada …
subject to considerable critique and debate locally. Health Systems in Transition: Canada …
[HTML][HTML] A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries
Background The use of a restrictive formulary, with placement determined through a drug-
reimbursement decision-making process, is one approach to managing drug expenditures …
reimbursement decision-making process, is one approach to managing drug expenditures …
Pharmaceutical pricing and reimbursement policies in Sweden
P Moïse, E Docteur - 2007 - papers.ssrn.com
This paper examines aspects of the policy environment and market characteristics of the
Swedish pharmaceutical sector, assesses the degree to which Sweden has achieved …
Swedish pharmaceutical sector, assesses the degree to which Sweden has achieved …
A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the Organisation for Economic Co-Operation and …
Background Publicly-funded drug plans vary in strategies used and policies employed to
reduce continually increasing pharmaceutical expenditures. We systematically reviewed the …
reduce continually increasing pharmaceutical expenditures. We systematically reviewed the …
[HTML][HTML] International experience in therapeutic value and value-based pricing: a rapid review of the literature
L Prieto-Pinto, N Garzón-Orjuela, P Lasalvia… - Value in Health …, 2020 - Elsevier
Objectives To characterize at a global level the concept of therapeutic value (TV) and
describe the experience of value-based pricing (VBP) policies in 6 reference countries …
describe the experience of value-based pricing (VBP) policies in 6 reference countries …
The effects of publicity on demand: The case of anti-cholesterol drugs
Over the past 10 years there has been increased recognition of the importance of publicity
as a means of generating product awareness. Despite this, previous research has seldom …
as a means of generating product awareness. Despite this, previous research has seldom …
[图书][B] A roadmap to a rational pharmacare policy in Canada
MA Gagnon - 2014 - nursesunions.ca
2010. Based on conservative hypotheses, the report showed that a public and universal
drug plan based on first-dollar coverage would not only improve access to prescription …
drug plan based on first-dollar coverage would not only improve access to prescription …
International comparison of comparative effectiveness research in five jurisdictions: insights for the US
Spurred by a desire to improve quality of care and to understand the relative value of
medical treatments, there has been a recent surge of interest in publicly funded comparative …
medical treatments, there has been a recent surge of interest in publicly funded comparative …